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Abstract: Traditionally, CD34 positive cells are predominantly found in the umbilical cord and bone marrow, thus
are considered as hematopoietic progenitors. Increasing evidence has suggested that the CD34+ cells represent a
distinct subset of cells with enhanced progenitor activity; CD34 is a general marker of progenitor cells in a variety of
cell types. Because the CD34 protein shows expression early on in hematopoietic and vascular-associated tissues,
CD34+ cells have enormous potential as cellular agents for research and for clinical cell transplantation. Directed
differentiation of embryonic stem cells will give rise to an inexhaustible supply of CD34+ cells, creating an exciting
approach for biomedical research and for regenerative medicine. Here, we review the main methods that have been
published for the derivation of CD34+ cells from embryonic stem cells; specifically those approaches the human
and nonhuman primate stem cells. We summarize current status of this field, compare the methods used, and
evaluate the issues in translating the bench science to bedside therapy.
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Introduction
The molecule CD34 was found in hematopoietic stem cells in 1984 [1]. It is a mucin-like transmembrane phosphoglycoprotein with molecular weight of 115 kD; the extracellular domain
contains the groups that are heavily sialylated
as well as glycosylated [2]. There is increasing
interest in analyzing and better understanding
the function of CD34 protein, What is known so
far is that CD34 protein plays an important role
in mediating cell-cell adhesion [3]; for example,
it mediates the attachment of stem cells to
bone marrow matrix or to stromal cell surfaces.
Several molecules have been identified as its
natural ligands including L-selectin (CD62L)
and Crk-like protein. When cell-cell interactions
with signaling molecules such as CD62L occur,
CD34+ cells may be mobilized and become proliferative. Therefore, it is believed that CD34mediated adhesion regulates cell differentiation and proliferation. Adult cells expressing
CD34 are quiescent under physiological condi-

tions but become active when homeostasis is
altered. Once mobilized, they propagate into
lineage-specific maturity according to the
nature of the signaling molecules. For the past
few decades, the focus on CD34+ cells has
been primarily in regard to hematopoiesis in
bone marrow. Now emerging evidence shows
that CD34+ progenitors exist within a variety of
tissues and can be mobilized. To date, it has
been demonstrated CD34 expressing cells, in
addition to hematopoietic stem cells, exist in
stromal, epithelial, and vascular tissues. In an
intriguing recent review [4], the authors implied
that CD34 is a general marker for a variety of
progenitors in tissues prior to commitment to
the lineage-specific differentiation.
CD34-based stem cell therapy has been under
development for more than a decade. Injection
of CD34+ hematopoietic stem cells selected by
monoclonal antibodies reconstituted bone marrow hematopoietic capacity after lethal irradiation of baboons [5]. The development of a ther-
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apy was accelerated by the collaborative effort
of the research team at Fred Hutchinson
Cancer Research Center and CellPro Inc. [6, 7].
Years later, the discovery of circulating endothelial progenitor cells positive for CD34 has
deeply impacted the growth of this field [8, 9],
extending beyond hematopoietic reconstitution
to the demonstration that the progenitors in the
circulation could repair the vascular damage.
To date, clinical trials using CD34+ cells have
been conducted to treat a variety of diseases
including acute and chronic ischemic heart failure, spinal cord injury, liver cirrhosis, and
peripheral vascular diseases. A recent PubMed
search using the keyword “CD34 cell therapy”
revealed 6,948 articles about this topic.
Because of the therapeutic potential, there is a
need to identify easily accessible and reliable
source of CD34+ cells, which are a primary
focus for future translational application.
Currently autologous or allogeneic CD34+ cells
from adult tissues are used in clinical trails, but
this strategy is probably not practical or maximally efficient or effective for large scale future
applications. With the advancement of capabilities to manipulate embryonic stem cells, the
controlled/directed differentiation of pluripotent stem cells has made it possible to obtain
large CD34+ populations of clinical relevance
[10]. This review focuses on the experimental
approaches to generate CD34+ cells from
embryonic stem cells (ESCs) and discusses
their properties.
CD34+ cell derivation based on recapitulation
of embryological events
As a result of the ability of ESCs to undergo differentiation, many functional cell types can be
generated in vitro; these cells are capable of
contributing to numerous tissues in vivo [10,
11]. Many investigators have been attempting
to recapitulate the embryonic events that lead
to the mature cells and direct the development
of embryonic stem cells along a specific pathway to acquire derivatives with particular functionalities [12]. The general strategy for this
approach is to remove the factors that maintain
the pluripotency of stem cells and to add factors that stimulate differentiation toward of
particular developmental fate. Specifically, confluent human ESC colonies are disrupted either
manually or enzymatically into small aggregates [13] or aggregates of a specified size
[14]; then, they are cultured on a low adherence
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plate, in suspension culture, or in semisolid
medium [15]. They become a virtually spheroid
structure, called an “embryoid body”. ESCs
inside an embryoid body undergo spontaneous
differentiation to some extent but exhibit rigorous changes in the presence of particular
growth factors in a time-dependent manner.
Although ESCs differentiate in either monolayer
culture or suspension culture, ESCs within
embryoid bodies may be a better model to initiate the early differentiation events and to
respond to cues that direct embryonic development [10]. This differentiation process parallels
normal morphogenesis and results in the formation of a micro-tissue; therefore, many investigators generate CD34 cells based on this
directed differentiation approach as reviewed
elsewhere [16].
Direct differentiation using co-culture system
Although ESC differentiation toward CD34+
cells can be carried out by recapitulating the
developmental process, this approach might
not be very efficient, because there are many
unknown factors involved in this process.
Several investigators have tried to enhance the
efficiency of the differentiation process by coculturing stimulating/signaling cells and ESCs,
since the development of functional cells naturally relies on intercellular interactions. When
human ESCs were cultured together with bone
marrow stromal cell line S17 [17] or OP9 [18],
higher yields and highly hematopoietic activities of CD34+ cells could be achieved. It has
been reported that up to 20% CD34+ cells and
10 million cells with 95% purity could be
obtained using that approach. The CD34+ cells
generated in this manner expressed hematopoiesis-associated genes and retained clonogenic potential after in vitro expansion. Further
culture on MS-5 stromal cells in the presence
of SCF, Flt-3, and IL-7 and IL-3 gave rise to lymphoid and myeloid lineages [18]. The application of co-culture has become more sophisticated recently as researchers aimed at creating
niches to enhance the generation of CD34+
progenitors. A recent example of this approach
established that when ESCs were cultured with
a mixture of macrophage and mesenchymal
stromal/stem cells, which may be reminiscent
of the bone marrow niche, CD34 cell yield was
not only increased, but their engraftment
potential was enhanced for a period of 16
weeks [19]. It seems reasonable that in vitro
Am J Stem Cells 2015;4(1):32-37
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recapitulation of an in vivo microenvironment
promotes the differentiation process. A niche, a
structural complex consisting of several types
of cells, might give a better outcome than the
environment provided by the single stromal cell
type.
Growth factors essential for CD34+ cell differentiation
Studies from developmental biology show that
three signaling pathways activin/Nodal, BMP,
and canonical Wnt regulate the development of
ESCs to blood cells [20]. Using a serum-free
culture medium, a group of investigators outlined the minimal factors required for directed
differentiation toward CD34+ cells [21]. They
proposed that four factors, including BMP-4,
activin A, bFGF and VEGF, were sufficient to
specify mouse ESCs to a hematopoietic fate;
but, the induction must be stepwise in order to
maximize CD34 expression. When human ESCs
were cultured in a fully defined serum-free
medium containing BMP-4, Flt-3 ligand, SCF,
thrombopoietin and VEGF, CD34+ cells were
generated [13]. For baboon ESC culture, we
found that those factors, together with bFGF,
gave rise to CD34+ cells after a stepwise differentiation process [14, 22]. The need for
bFGF was also suggested by another report
[23].
It has been reported that CD34+ yield could
be enhanced if some signaling pathways
are inhibited. Earlier studies showed that
an efficient method to generate CD34+ cells
involved inhibition of MEK/ERK signaling and
activation of BMP-4 signaling at the same time
[24]. A more recent report demonstrated that
inhibition of glycogen synthase kinase-3 (GSK3) could increase the production of CD34+/
KDR+ cells [25].
Integrated system for progenitor generation
To best mimic the embryonic development of
CD34-related cells, a combined cultured system has been reported. While embryoid body
formation mirrors normal development, co-culturing with stromal cells may release growth
factors that enhance the generation of wellfunctioning progenitors. A representative of
such a system was the initial embryoid body
method to form a mesodermal structure for 7
days followed by co-culture with OP9 stromal
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cells plated on the culture dishes for another 7
days [26]. The authors that describe this
approach state their protocol enabled efficient
expansion of several types of CD34+ cells with
long-term repopulating ability.
Hope and hype of CD34+ cells in regenerative
medicine
Based on the current pace of stem cell research
and the development of improved strategies for
enhancing efficiency, there is hope that stem
cell therapies may change the future of medical
modalities [10, 16, 27]. However, embryonic
derived CD34+ progenitors have not been tested in a clinical setting. By comparison to retinal
pigment epithelium progenitor cells and neuronal progenitor cells that are in clinical trials [28,
29], ESC derived CD34+ cells have been left
behind. Following are some of the future explorations that are required to unleash the promise of CD34+ cell therapy to become a reality.
First, we need to establish the procedure to formulate CD34+ progenitor cells as therapeutic
agents. The differentiation of CD34+ cells from
ESCs is an extremely spatial- and temporaldependent event, and the signaling pathways
directing lineage commitment are not entirely
clear; consequently, a robust and reproducible
protocol remains to be defined [30]. It is possible that different CD34+ subpopulations directed by specific differentiation methods have distinct therapeutical potentials that are currently
unknown. Many progenitor cells may express
this molecule, as mentioned above; thus
further characterization is essential to determine their differentiation fates and the functional characteristics of their derivatives. For
example, CD34brignt/CD31+/KDR+/CD45+ may
be the cells with hemato-endothelial potential
[31], while CD34+/CD43-/CD45+ cells represent hematopoietic progenitors with myeloid lineage potential [32]. Therefore, it is important to
know the composition of CD34+ formulated
cell lines, since subpopulations positive for
CD34 have the biological functions that remain
to be explored.
Second, there is a strong demand to establish
bioassays to verify what type of cells are
required for a specific clinical need, as part of
mode of action studies. For a long time in the
field of ESC derivative studies, there have been
more efforts focusing on gene expression pro-
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filing, in vitro functionality testing, and nude
mice transplantation, and less on cellular
behaviors in a natural environment where the
cells will need to function. Alternatively, we
need a bioassay to test the functional characteristics of the derivatives in vitro or ex vivo.
The bioassay needs to involve a live tissue in
order to assess or standardize the activity of
the agents containing CD34+ cells. Using a living section of either a tissue or an organ will
enable us to track the adhesion, homing, and
propagation of engrafted cells in the very site
that cell replacement will be required. In our
studies, we established an ex vivo bioassay to
evaluate the functional reconstitution of CD34+
cells derived from baboon ESCs. We tested the
ability of these cells to repair the damage
induced by experimental manipulation [14, 22].
By doing so, we could characterize the therapeutic cells in an interactive environment, in
which we could not only access the functional
characteristics but also the suitable maturation
stage. In the future, we will use this assay to
standardize the protocols for vascular progenitor cells in order to determine reliably and consistently the functionalities of candidate cells
and to adjust experimental protocols to meet
the requirements for the future medical use of
ESC-derived cells.
Third, the action of therapeutic cells needs to
be tested in a relevant animal model. We all
must establish that the derivatives are capable
of long-term engraftment in animals with appropriate multi-lineage proliferation and differentiation to execute their therapeutic effects.
However, the animals to be grafted should be
physiologically close to humans in order to provide the correct information for the translational medicine. Scientists have used animals such
as sheep [19, 33], and chicken [34], and
mouse. for this type of research. However,
increasing evidence indicates that dramatically
different mechanisms regulating stem cell differentiation exist between species. Despite
striking similarities exist between mouse and
human development, numerous stem cell therapies developed in mice have failed when tested in humans [35, 36]. One of the reasons may
be attributable to species-specific differences
in signaling pathways that maintain pluripotency and affect differentiation. The need for an
animal model that is more similar to humans
prompted us to initiate research that uses a
large nonhuman primate, the baboon, for early
35

stage translational research to establish the
feasibility of stem cell-derived cell therapy. We
have developed techniques that allow us to
generate endothelial progenitors from baboon
ESCs whose phenotypes are found in adult vasculatures; and we have developed the baboon
as a model for research on cardiovascular disease in order to test rigorously the effectiveness and safety of stem cell derived vascular
progenitors in primates.
Although a plethora of CD34+ cell generation
methods have been reported [37], the rationale
of the differentiation approach remains unexplained in most instances. Similarly, few protocols have been validated yet. However, successful ESC-based therapies depend developing a simple and efficient protocol for the differentiation of ESCs into large number of functional CD34+ progenitors. This is a major focus
of translational stem cell biology. We believed
that the integration of understanding the early
events of embryogenesis in culture and validating a scientifically sound primate test system
for identifying useful cell type(s) will accelerate
the CD34+ cell therapy for treating patients.
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